Logo

Transgenomic MX-ICP Panel for Lung Cancer

Aug 19, 2015

Transgenomic has launched a multiplexed ICE COLD PCR (MX-ICP) lung cancer panel with epidermal growth factor receptor (EGFR) analysis. The panel covers key actionable mutations while providing precision detection levels as low as 0.01 percent. Characteristic mutations in EGFR are found in many patients with lung tumors, and these mutations may be associated with susceptibility or resistance to certain targeted cancer drugs. The panel includes EGFR exons 18-21 to determine NSCLC tumor sensitivity or resistance to tyrosine kinase inhibitors. The MX-ICP technology in the panel generates highly accurate results from small amounts of blood or tissue samples and is available for diagnostic use through the company's CLIA laboratory, said Transgenomic in a statement.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.